Literature DB >> 7521438

[Cardiovascular complications of interferon therapy in chronic hepatitis C].

H Kouno1, S Aimitsu, Y Ikemoto, T Nakanishi, G Kajiyama.   

Abstract

Severe cardiovascular complications (myocardial infarction, ventricular fibrillation et al.) have been reported in patients who have been administrated extremely high dose interferon (IFN) or cardio-toxic drugs, or who have had cardiovascular diseases. But cardiomyopathy, myocarditis and atrioventricular block were reported in patients who administered low dose IFN and no cardio-toxic drugs or had no cardiovascular diseases. We report here cardiovascular complications during IFN therapy for chronic hepatitis C. Cardiovascular complications that necessitated stopping IFN administration in 643 treated chronic hepatitis C patients are observed in 4 patients (0.62%). Second-degree atrioventricular block occurred in two patients, myocarditis in one patient and severe sinus bradycardia in one patient. So we have to check risk factors of cardiovascular complications before starting IFN therapy and electrocardiogram during IFN therapy.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7521438

Source DB:  PubMed          Journal:  Nihon Rinsho        ISSN: 0047-1852


  4 in total

Review 1.  Role of interferon alpha in endothelial dysfunction: insights into endothelial nitric oxide synthase-related mechanisms.

Authors:  Joy N Jones Buie; Jim C Oates
Journal:  Am J Med Sci       Date:  2014-08       Impact factor: 2.378

2.  A case of polymyositis in a chronic hepatitis C patient treated with peg-interferon-alpha 2b and ribavirin therapy.

Authors:  Yusuke Okuma; Kiminori Kimura; Shunichi Saeki; Tsunekazu Hishima; Seishu Hayashi
Journal:  Clin J Gastroenterol       Date:  2009-08-06

Review 3.  Treatment of hepatitis C virus infection and associated vascular complications: a literature review.

Authors:  Reza Karbasi-Afshar
Journal:  Iran J Med Sci       Date:  2014-05

4.  Is combination therapy for chronic hepatitis C toxic for cardiac function?

Authors:  Ramzy Almawardy; Walid Elhammady; Nasser Mousa; Sherif Abotaleb
Journal:  Hepat Mon       Date:  2012-08-20       Impact factor: 0.660

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.